Literature DB >> 22345475

Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions.

Jérôme Bouchet1, Cécile Hérate, Carolin A Guenzel, Christel Vérollet, Annika Järviluoma, Julie Mazzolini, Salomeh Rafie, Patrick Chames, Daniel Baty, Kalle Saksela, Florence Niedergang, Isabelle Maridonneau-Parini, Serge Benichou.   

Abstract

HIV-1 Nef is essential for AIDS pathogenesis, but this viral protein is not targeted by antiviral strategies. The functions of Nef are largely related to perturbations of intracellular trafficking and signaling pathways through leucine-based and polyproline motifs that are required for interactions with clathrin-associated adaptor protein complexes and SH3 domain-containing proteins, such as the phagocyte-specific kinase Hck. We previously described a single-domain antibody (sdAb) targeting Nef and inhibiting many, but not all, of its biological activities. We now report a further development of this anti-Nef strategy through the demonstration of the remarkable inhibitory activity of artificial Nef ligands, called Neffins, comprised of the anti-Nef sdAb fused to modified SH3 domains. The Neffins inhibited all key activities of Nef, including Nef-mediated CD4 and major histocompatibility complex class I (MHC-I) cell surface downregulation and enhancement of virus infectivity. When expressed in T lymphocytes, Neffins specifically inhibited the Nef-induced mislocalization of the Lck kinase, which contributes to the alteration of the formation of the immunological synapse. In macrophages, Neffins inhibited the Nef-induced formation of multinucleated giant cells and podosome rosettes, and it counteracted the inhibitory activity of Nef on phagocytosis. Since we show here that these effects of Nef on macrophage and T cell functions were both dependent on the leucine-based and polyproline motifs, we confirmed that Neffins disrupted interactions of Nef with both AP complexes and Hck. These results demonstrate that it is possible to inhibit all functions of Nef, both in T lymphocytes and macrophages, with a single ligand that represents an efficient tool to develop new antiviral strategies targeting Nef.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22345475      PMCID: PMC3347381          DOI: 10.1128/JVI.06329-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  A guided tour into subcellular colocalization analysis in light microscopy.

Authors:  S Bolte; F P Cordelières
Journal:  J Microsc       Date:  2006-12       Impact factor: 1.758

2.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

3.  Three-dimensional migration of macrophages requires Hck for podosome organization and extracellular matrix proteolysis.

Authors:  Céline Cougoule; Véronique Le Cabec; Renaud Poincloux; Talal Al Saati; Jean-Louis Mège; Guillaume Tabouret; Clifford A Lowell; Nathalie Laviolette-Malirat; Isabelle Maridonneau-Parini
Journal:  Blood       Date:  2009-11-06       Impact factor: 22.113

Review 4.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

Review 5.  The macrophage in HIV infection.

Authors:  J M Orenstein
Journal:  Immunobiology       Date:  2001-12       Impact factor: 3.144

6.  Matrix architecture dictates three-dimensional migration modes of human macrophages: differential involvement of proteases and podosome-like structures.

Authors:  Emeline Van Goethem; Renaud Poincloux; Fabienne Gauffre; Isabelle Maridonneau-Parini; Véronique Le Cabec
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

7.  Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking.

Authors:  A Mangasarian; V Piguet; J K Wang; Y L Chen; D Trono
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  The tyrosine binding pocket in the adaptor protein 1 (AP-1) mu1 subunit is necessary for Nef to recruit AP-1 to the major histocompatibility complex class I cytoplasmic tail.

Authors:  Elizabeth R Wonderlich; Maya Williams; Kathleen L Collins
Journal:  J Biol Chem       Date:  2007-12-11       Impact factor: 5.157

Review 9.  Hematopoietic cell kinase (Hck) isoforms and phagocyte duties - from signaling and actin reorganization to migration and phagocytosis.

Authors:  Romain Guiet; Renaud Poincloux; Jerôme Castandet; Louis Marois; Arnaud Labrousse; Véronique Le Cabec; Isabelle Maridonneau-Parini
Journal:  Eur J Cell Biol       Date:  2008-06-05       Impact factor: 4.492

10.  Small molecule inhibition of HIV-1-induced MHC-I down-regulation identifies a temporally regulated switch in Nef action.

Authors:  Jimmy D Dikeakos; Katelyn M Atkins; Laurel Thomas; Lori Emert-Sedlak; In-Ja L Byeon; Jinwon Jung; Jinwoo Ahn; Matthew D Wortman; Ben Kukull; Masumichi Saito; Hirokazu Koizumi; Danielle M Williamson; Masateru Hiyoshi; Eric Barklis; Masafumi Takiguchi; Shinya Suzu; Angela M Gronenborn; Thomas E Smithgall; Gary Thomas
Journal:  Mol Biol Cell       Date:  2010-08-11       Impact factor: 4.138

View more
  11 in total

Review 1.  Small molecule inhibitors of the HIV-1 virulence factor, Nef.

Authors:  Thomas E Smithgall; Gary Thomas
Journal:  Drug Discov Today Technol       Date:  2013-12

Review 2.  Single domain antibodies for the knockdown of cytosolic and nuclear proteins.

Authors:  Thomas Böldicke
Journal:  Protein Sci       Date:  2017-03-24       Impact factor: 6.725

Review 3.  SH3 domains come of age.

Authors:  Brian K Kay
Journal:  FEBS Lett       Date:  2012-06-05       Impact factor: 4.124

4.  Selection of intracellular single-domain antibodies targeting the HIV-1 Vpr protein by cytoplasmic yeast two-hybrid system.

Authors:  Julie Matz; Cécile Hérate; Jérôme Bouchet; Nelson Dusetti; Odile Gayet; Daniel Baty; Serge Benichou; Patrick Chames
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 5.  Single-Domain Antibodies As Therapeutics against Human Viral Diseases.

Authors:  Yanling Wu; Shibo Jiang; Tianlei Ying
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

Review 6.  HIV-1 Infection of T Lymphocytes and Macrophages Affects Their Migration via Nef.

Authors:  Christel Vérollet; Véronique Le Cabec; Isabelle Maridonneau-Parini
Journal:  Front Immunol       Date:  2015-10-06       Impact factor: 7.561

7.  Structural basis for the inhibition of HIV-1 Nef by a high-affinity binding single-domain antibody.

Authors:  Sebastian Lülf; Julie Matz; Marie-Christine Rouyez; Annika Järviluoma; Kalle Saksela; Serge Benichou; Matthias Geyer
Journal:  Retrovirology       Date:  2014-03-13       Impact factor: 4.602

8.  Uracil DNA glycosylase interacts with the p32 subunit of the replication protein A complex to modulate HIV-1 reverse transcription for optimal virus dissemination.

Authors:  Cecile Herate; Clarisse Vigne; Carolin A Guenzel; Marie Lambele; Marie-Christine Rouyez; Serge Benichou
Journal:  Retrovirology       Date:  2016-04-12       Impact factor: 4.602

9.  Phospholipid Scramblase 1 Modulates FcR-Mediated Phagocytosis in Differentiated Macrophages.

Authors:  Cecile Herate; Ghania Ramdani; Nancy J Grant; Sabrina Marion; Stephane Gasman; Florence Niedergang; Serge Benichou; Jerome Bouchet
Journal:  PLoS One       Date:  2016-01-08       Impact factor: 3.240

Review 10.  Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy.

Authors:  Muhamad Alif Che Nordin; Sin-Yeang Teow
Journal:  Molecules       Date:  2018-02-06       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.